Your Alzheimer’s test results are ready online. Would you open them?

As genetic and blood-based testing for Alzheimer’s disease expands, researchers examine what happens when older adults learn sensitive health information through a digital platform rather than directly from a healthcare professional.

Study: Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results. Image Credit: Rawpixel.com

In a recent study published in the journal JAMA Neurology, researchers examined whether a patient-centered digital platform was noninferior to clinician-mediated telehealth disclosure of apolipoprotein E (APOE) genotype results in terms of knowledge, anxiety, and disease-specific distress. The researchers also compared outcomes following the disclosure of plasma phosphorylated tau 217 (p-tau217) results.

The research was conducted by scientists from Banner Alzheimer’s Institute, the Perelman School of Medicine at the University of Pennsylvania, and Fox Chase Cancer Center, part of Temple University Health System, in the United States.

Background

What happens when patients receive information about their risk of Alzheimer’s disease before speaking with a healthcare professional? Under the United States (US) 21st Century Cures Act, most medical test results must be made available to patients without delay. This means patients may see genetic and biomarker findings without a healthcare professional present. APOE genotyping can provide information on genetic susceptibility to Alzheimer’s disease, while blood-based biomarkers such as p-tau217 can indicate underlying disease pathology.

Typically, clinicians are responsible for disclosing this information; however, limited availability of trained healthcare professionals and the substantial time required for counseling may restrict access. Digital platforms could enhance disclosure by providing structured education and tailored information. The increasing adoption of anti-amyloid therapies, including lecanemab and donanemab, has heightened the importance of these assessments for guiding treatment decisions and evaluating associated risks. Further research is necessary to evaluate the safety and effectiveness of digital disclosure methods across diverse clinical populations.

About the study

The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) trial was a decentralized, fully remote, randomized noninferiority trial conducted in the contiguous United States. Recruitment ran from October 2024 to February 2025, and follow-up was completed in November 2025. Participants were recruited through GeneMatch, a research enrollment program that provides APOE genotyping and education about genetic risk.

Eligible participants were aged 60 to 80 years, had previously undergone APOE testing without result disclosure, had Internet access, could speak English, and were willing to provide blood samples. Individuals with elevated depressive symptoms, indicators of suicidality, untreated or unstable major psychiatric illness, or communication difficulties were excluded. Participants were randomized 2:1 to receive APOE test results through a patient-controlled online platform or from a genetic counselor via a telehealth session.

The digital intervention included a choice between a secure web-based platform and a short message service (SMS)-based chat option. Educational materials provided necessary information and optional detailed explanations, including personalized risk estimates for developing mild cognitive impairment or dementia by age 85. Participants could request clinician assistance before, after, or instead of digital disclosure.

Six months after APOE disclosure, participants were offered optional p-tau217 testing and disclosure through their assigned method, with a study physician communicating results in the telehealth group. The researchers analyzed blood samples using a research-use-only assay and classified p-tau217 results as negative, intermediate, or positive.

Primary outcomes included changes in Alzheimer’s disease-related knowledge, anxiety measured using the Patient-Reported Outcomes Measurement Information System, and disease-specific distress. Assessments occurred at baseline and at 1 to 7 days, 6 weeks, and 6 months after APOE disclosure. Follow-up after p-tau217 disclosure lasted four weeks.

The researchers used predefined statistical thresholds to determine whether digital APOE disclosure produced outcomes not meaningfully worse than clinician-mediated disclosure. Outcomes following p-tau217 disclosure were assessed through secondary comparisons.

Study results

Of the 13,033 GeneMatch members invited to participate, 2,052 accepted the invitation, and 813 underwent eligibility screening. Of these, 666 participants were randomized, and 651 received APOE results and were included in the primary analyses. Of these, 216 were in the clinician-mediated disclosure group, and 435 were in the digital disclosure group. Participants had an average age of 68 years, and 67% were women.

Of the participants, 90% were White, 78% had at least a college education, 52% lived in rural areas, and 67% reported a family history of Alzheimer’s disease. Regarding APOE ε4 status, 10% carried two copies of the risk-associated allele, 58% carried one copy, and 32% were noncarriers. More than one-third scored below a commonly used cognitive screening threshold for cognitive impairment. Baseline characteristics were comparable between the groups.

Digital disclosure meets primary trial objectives

The primary analyses demonstrated that digital disclosure was noninferior to clinician-mediated disclosure for the primary outcomes of Alzheimer’s disease-related knowledge, anxiety, and distress. These findings were based on the results of the first assessment (conducted one to seven days after disclosure) and were consistent at all follow-up assessments. Per-protocol analyses yielded similar results.

Overall, 90% of randomized participants completed optional digital education before disclosure, and only two participants assigned to digital disclosure requested a genetic counselor.

Clinician-led disclosure receives higher satisfaction ratings

Secondary analyses revealed some differences between delivery methods. Participants who received their results digitally reported slightly more negative psychological responses to learning their genetic results during the first week after disclosure than those who received telehealth services. The difference was small, likely not clinically significant, and was not sustained at subsequent assessments. Satisfaction was high in both groups, but average scores were higher in the telehealth group than in the digital group (4.8 versus 4.3 out of 5).

Incorrect recall of APOE results at six weeks was more frequent among participants who received their results digitally than among those receiving clinician-mediated disclosure (14% versus 6%). Recall differences were not statistically significant within the first week after disclosure or at six months. By six months, correct recall had declined to 87% in the telehealth group and 83% in the digital group, suggesting that participants may benefit from continued access to their results and educational materials.

Exploratory subgroup analyses showed some short-term differences among APOE ε4 carriers. Participants receiving telehealth disclosure experienced a small reduction in disease-specific distress during the first week, while those receiving digital disclosure experienced a slight increase. Digital disclosure was also associated with slightly higher negative responses to learning genetic risk. These differences were small, unlikely to be clinically significant, and did not persist.

Among APOE ε4 noncarriers, the study noted no significant differences in knowledge or psychological outcomes. Participants in this subgroup also rated telehealth sessions more favorably. No significant differences between delivery methods emerged when the researchers grouped participants according to their baseline cognitive screening scores.

Blood biomarker disclosure produces similar psychological outcomes

Among the 565 participants who provided blood samples, 47% had negative p-tau217 results, 31% had intermediate results, and 22% had positive results. In total, 500 participants completed optional p-tau217 disclosure, including 163 in the telehealth group and 337 in the digital group. No statistically significant overall between-group differences were identified in knowledge, anxiety, disease-specific distress, depression-related symptoms, perceived risk, or other secondary outcomes.

Results remained broadly comparable across negative, intermediate, and positive biomarker categories, but participants with intermediate results reported slightly higher satisfaction with clinician-mediated disclosure. Correct recall was 97% in the telehealth group and 98% in the digital group within the first week after disclosure. At four weeks, the corresponding figures were 95% and 91%.

Conclusions

The eSMARTER randomized clinical trial demonstrated that patient-centered digital disclosure of APOE genotype results was noninferior to clinician-mediated telehealth disclosure regarding Alzheimer’s disease-related knowledge, anxiety, and disease-specific distress. No significant overall differences in major outcomes were observed following optional p-tau217 disclosure.

Clinician-mediated disclosure was associated with higher satisfaction and small short-term differences in secondary outcomes. The predominantly White, highly educated, self-selected research population and psychological screening limit the generalizability of the findings. The trial also lacked sufficient statistical power to rule out differences in the need for immediate or additional psychological support among certain subgroups.

The study did not evaluate conventional electronic health portals that provide laboratory results with limited explanation, and the six-month interval between genetic and biomarker disclosure differed from routine clinical practice. The digital platform also lacked voice-over narration, requiring users to read the information presented on their screens.

The findings indicate that structured digital platforms represent a viable alternative for communicating sensitive genetic and biomarker information, especially when preferred by appropriately selected individuals or when clinician-mediated disclosure is unavailable or impractical. The eSMARTER platform is currently not available as a standalone software product.

The US National Institute on Aging funded the study and had no role in its conduct or reporting. Several authors reported financial ties to pharmaceutical and biotechnology companies, including study co-author Eric M. Reiman, a co-founder, advisor, and shareholder of ALZPath, which produces an antibody licensed for use on several testing platforms, including the Roche platform employed in the trial.

Source:

Journal reference:
  • Langbaum, J. B., Erickson, C. M., Langlois, C. M., Wood, E. M., Egleston, B. L., Harkins, K., Mim, R., John, S., Brown, C., Brown, S., Howe, S., Cacioppo, C., Eppelmann, L., Enos, J., Salata, H., De Santiago, D., Largent, E. A., Reiman, E. M., Denkinger, M. N., Ashton, N. J., Roberts, J. S., Karlawish, J., & Bradbury, A. R. (2026). Digital delivery of apolipoprotein E genotype and phosphorylated tau 217 results: The eSMARTER randomized clinical trial. JAMA Neurology. DOI: 10.1001/jamaneurol.2026.4279, https://jamanetwork.com/journals/jamaneurology/fullarticle/2856813
Vijay Kumar Malesu

Written by

Vijay Kumar Malesu

Vijay holds a Ph.D. in Biotechnology and possesses a deep passion for microbiology. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. Through his research and studies, he has gained expertise in various aspects of microbiology, which includes microbial genetics, microbial physiology, and microbial ecology. Vijay has six years of scientific research experience at renowned research institutes such as the Indian Council for Agricultural Research and KIIT University. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges.    

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kumar Malesu, Vijay. (2026, November 19). Your Alzheimer’s test results are ready online. Would you open them?. News-Medical. Retrieved on November 19, 2026 from https://www.news-medical.net/news/20261119/Your-Alzheimere28099s-test-results-are-ready-online-Would-you-open-them.aspx.

  • MLA

    Kumar Malesu, Vijay. "Your Alzheimer’s test results are ready online. Would you open them?". News-Medical. 19 November 2026. <https://www.news-medical.net/news/20261119/Your-Alzheimere28099s-test-results-are-ready-online-Would-you-open-them.aspx>.

  • Chicago

    Kumar Malesu, Vijay. "Your Alzheimer’s test results are ready online. Would you open them?". News-Medical. https://www.news-medical.net/news/20261119/Your-Alzheimere28099s-test-results-are-ready-online-Would-you-open-them.aspx. (accessed November 19, 2026).

  • Harvard

    Kumar Malesu, Vijay. 2026. Your Alzheimer’s test results are ready online. Would you open them?. News-Medical, viewed 19 November 2026, https://www.news-medical.net/news/20261119/Your-Alzheimere28099s-test-results-are-ready-online-Would-you-open-them.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Yale study explores why arthritis returns after cancer immunotherapy